Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$33.46 +3.2%	$30.58	$23.95 ▼ $52.34	$5.33B	0.15	1.56 million shs	2.02 million shs
LEGN Legend Biotech	$28.97 +2.4%	$32.06	$27.34 ▼ $60.87	$5.32B	0.2	1.29 million shs	1.42 million shs
NUVL Nuvalent	$74.76 +4.7%	$71.06	$55.54 ▼ $113.51	$5.35B	1.42	492,199 shs	682,194 shs
PNT POINT Biopharma Global		$12.98	$6.57 ▼ $14.35	$1.33B	N/A	1.44 million shs	3.29 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-2.67%	-3.19%	+9.05%	+3.44%	-13.84%
LEGN Legend Biotech	-1.63%	-0.14%	-18.47%	-22.95%	-32.13%
NUVL Nuvalent	-1.16%	-3.03%	-5.01%	-4.65%	+6.48%
PNT POINT Biopharma Global	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IONS Ionis Pharmaceuticals	4.3907 of 5 stars	4.3	1.0	0.0	3.0	3.5	3.3	0.6
LEGN Legend Biotech	3.2967 of 5 stars	4.5	2.0	0.0	0.0	3.4	1.7	0.6
NUVL Nuvalent	2.5076 of 5 stars	3.5	2.0	0.0	0.0	3.0	3.3	0.0
PNT POINT Biopharma Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.65	Moderate Buy	$56.67	69.36% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	163.03% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	54.49% Upside
PNT POINT Biopharma Global	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PNT, IONS, NUVL, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/14/2025	LEGN Legend Biotech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$88.00 ➝ $71.00
5/14/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00
5/1/2025	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00
5/1/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $50.00
4/30/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
4/22/2025	LEGN Legend Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$84.00 ➝ $84.00
4/16/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/15/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$717.25M	7.42	N/A	N/A	$3.70 per share	9.04
LEGN Legend Biotech	$728.30M	7.31	N/A	N/A	$6.88 per share	4.21
NUVL Nuvalent	N/A	N/A	N/A	N/A	$10.94 per share	N/A
PNT POINT Biopharma Global	$226.58M	0.00	N/A	13.31	$4.68 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	8/7/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.59	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	8/8/2025 (Estimated)
NUVL Nuvalent	-$126.22M	-$4.39	N/A	N/A	N/A	N/A	-28.63%	-27.15%	8/14/2025 (Estimated)
PNT POINT Biopharma Global	$98.29M	$0.90	13.89	N/A	N/A	39.62%	21.10%	18.28%	N/A

Latest PNT, IONS, NUVL, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
3/11/2025	Q4 2024	LEGN Legend Biotech	-$0.39	$0.07	+$0.46	$0.07	$179.00 million	$186.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
PNT POINT Biopharma Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	2.12	8.47	8.82
LEGN Legend Biotech	0.27	4.98	4.90
NUVL Nuvalent	N/A	23.07	23.07
PNT POINT Biopharma Global	0.01	9.14	9.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
LEGN Legend Biotech	70.89%
NUVL Nuvalent	97.26%
PNT POINT Biopharma Global	59.53%

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	2.60%
LEGN Legend Biotech	0.02%
NUVL Nuvalent	12.52%
PNT POINT Biopharma Global	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable
LEGN Legend Biotech	1,070	183.76 million	182.60 million	Optionable
NUVL Nuvalent	40	71.60 million	62.16 million	Optionable
PNT POINT Biopharma Global	129	106.57 million	89.52 million	Optionable

PNT, IONS, NUVL, and LEGN Headlines

Recent News About These Companies

Lantheus on POINT in radio-oncology with $2bn licensing deal

September 14, 2024 | pharmaphorum.com

Sustainability: A Key Differentiator as Biopharma Faces Momentum Challenges, According to Global Survey by Cytiva

August 21, 2024 | genengnews.com

Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado

July 24, 2024 | markets.businessinsider.com

How to deliver an effective global strategic brand plan

July 19, 2024 | pharmaphorum.com

What's Going On With GT Biopharma Stock?

May 20, 2024 | msn.com

How Merck is stepping up for patients

May 19, 2024 | pharmaphorum.com

Point Digital Finance prints second HEI RMBS

May 9, 2024 | globalcapital.com

Investing in biopharma innovation: Can you stay one step ahead?

April 8, 2024 | bloomberg.com

Global Point of Care Molecular Diagnostics Industry Aims for a Striking US$11.1 Billion Market by 2033, Fueled by a 9.7% CAGR | FMI

March 14, 2024 | fmiblog.com

Reshaping The Global Neopentyl Glycol Dicaprate Market With Latest Trends And Market Opportunities

February 21, 2024 | opprairie.com

Comprehensive Overview of the Pharmaceutical Grade Ambrisentan Market along with Emerging Trends, Challenges, and Potential Threats

February 13, 2024 | opprairie.com

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

January 8, 2024 | businesswire.com

Lilly Completes Acquisition of POINT Biopharma

December 27, 2023 | finance.yahoo.com

POINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition Prospects

December 22, 2023 | markets.businessinsider.com

Brookline Capital Downgrades POINT Biopharma Global (PNT)

December 22, 2023 | msn.com

POINT Biopharma Global Stock (NASDAQ:PNT), Guidance and Forecast

December 22, 2023 | benzinga.com

Lilly extends tender offer for POINT Biopharma to Dec. 22

December 18, 2023 | msn.com

Why POINT Biopharma Global Is At Least A Hold On Disappointing Readout

December 18, 2023 | seekingalpha.com

Lantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Results

December 18, 2023 | markets.businessinsider.com

POINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should Know

December 8, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
By Leo Miller | May 27, 2025
View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
By Ryan Hasson | May 5, 2025
View Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
By Thomas Hughes | May 14, 2025
View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start
Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
By Leo Miller | May 19, 2025
View Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves

PNT, IONS, NUVL, and LEGN Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$33.46 +1.03 (+3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$33.46 -0.01 (-0.01%)

As of 04:40 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Legend Biotech NASDAQ:LEGN

$28.97 +0.68 (+2.40%)

Closing price 04:00 PM Eastern

Extended Trading

$28.95 -0.02 (-0.07%)

As of 04:43 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Nuvalent NASDAQ:NUVL

$74.76 +3.33 (+4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$74.76 -0.01 (-0.01%)

As of 04:04 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

POINT Biopharma Global NASDAQ:PNT

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time